ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#02

May 2026

"Rhino Tranq" Is Spreading Fast, and It Has No Human Reversal Agent

NFLIS medetomidine detections jumped from 247 in 2023 to 2,616 in 2024 to 8,233 in 2025. The DEA describes it as 200 to 300 times more potent than xylazine, and it is now detectable in over a third of opioid-positive samples at 10 of 20 national surveillance sites. Concentrated in the Northeast but actively spreading. Like xylazine, naloxone reverses the respiratory depression but not the deep sedation. The withdrawal syndrome is severe: hypertension, anxiety, and fluctuating consciousness consistent with abrupt clonidine cessation; ICU-level management is required in serious cases. No FDA-approved human reversal agent exists.

Source: DEA Public Safety Advisory  ·  May 12, 2026; NFLIS surveillance data

Cannabis Rescheduling Fractures in Congress: What It Means for Testing Programs Today

On April 23, the DOJ moved FDA-approved and state-licensed medical cannabis to Schedule III. By May 15, the House Appropriations Committee voted 32 to 28 to block federal funding for implementing that order, and the full House separately passed a bipartisan amendment allowing VA physicians to recommend medical cannabis to veterans. The practical effect right now: recreational cannabis remains Schedule I, DOT testing programs are unchanged pending HHS guidance, and the legal status of cannabis on standard panels is genuinely unsettled. The DEA holds a formal hearing June 29 through July 15; that is the next meaningful inflection point. For drug courts and employer clients, the guidance is to hold current panels and document the uncertainty, not to act prematurely.

DOJ Order  ·  DEA / Congress  ·  April 23 – May 15, 2026

DOT Oral Fluid Final Rule: Effective June 10 (24 Days Out)

The DOT published its final rule amending 49 CFR Part 40 on May 11. Effective date is June 10. The rule authorizes directly observed urine collection as an interim measure where oral fluid testing is not yet available. An 18-month implementation grace period begins once a second HHS-certified oral fluid lab is officially announced. A separate May 4 FDA proposed rule would remove the 510(k) clearance requirement that has been the main bottleneck for lab certification. That second lab could be announced sooner than expected. If you consult any DOT-regulated employers, June 10 is your checkpoint for confirming their interim collection policy is documented.

Federal Register  ·  DOT / HHS  ·  May 11, 2026

ADDICTION

"Optimal Duration of Medication Treatment for Opioid Use Disorder"

Hayes et al. analyzed 32,348 U.S. veterans on buprenorphine, methadone, or XR-naltrexone and found that survival benefit continues accruing through at least 4 to 5 years of MOUD retention. The largest marginal gain occurs around year 2. The authors explicitly state the current 6-month CMS quality metric is "likely insufficient regardless of individual mortality risk." For OTP providers, this paper gives you direct evidence to push back on payers, drug courts, and referral sources using a 6-month benchmark as a finish line. It is also a practical tool for patient conversations about long-term treatment expectations.

Hayes et al., 2026  ·  Read it →

JAMA NETWORK OPEN

"Expert Consensus on Hospital MOUD Initiation in the High-Potency Synthetic Opioid Era"

A 42-expert Delphi study published May 7 reached consensus that rapid methadone initiation and both high-dose and low-dose buprenorphine initiation are appropriate for hospitalized patients using fentanyl and other high-potency synthetics. Notably, traditional buprenorphine induction was rated as having "uncertain appropriateness" in this population, a direct challenge to the standard CIWA-adjacent approach many hospital programs still default to. For Roanoke CTC patients who cycle through hospital presentations, this consensus matters: you want the admitting team initiating the right protocol before discharge.

Expert consensus, JAMA Network Open, May 7, 2026  ·  Read it →